



Bioethics

ISSN: 2989-5448 (Online)

Publisher: Tomorrow's Research Publications (TRP)

An International Peer-Reviewed Open Access Journal

Perspective

The Moral Status of Human-Animal Chimeras in Regenerative Medicine

Giulia Lindqvist^{1*}, Lars Greco¹ and Sofia Kovacs²

¹Center for Medical Ethics and Law, Northmoor School of Public Health Ethics, United Kingdom

²Institute for Health Policy and Ethics, Shannon University Centre for Bioethics, Ireland

ABSTRACT

Interspecies blastocyst complementation and related techniques for creating human-animal chimeras have moved from theoretical possibility to active laboratory practice, driven largely by the promise of growing humanized organs for transplantation.

This progress has outpaced the philosophical literature's ability to settle a prior question: how much human biological contribution, of what kind and in what tissue, changes an animal's moral status.

This perspective surveys capacity-based, kind-based, and degree-based frameworks for moral status and applies them to three chimera types of current scientific interest -- humanized-organ pigs, neural chimeras and brain organoid transplants, and early-stage monkey-human embryos.

We argue that these three cases warrant markedly different levels of ethical concern, with humanized-organ research raising primarily confinement and welfare questions while neural chimera research raises harder, still largely unresolved questions about capacity and detection.

We conclude that governance structures for chimera research have not kept pace with the science, and that resolving disagreement between frameworks matters less, in practice, than building oversight bodies equipped to actually apply any of them.

Keywords: human-animal chimera; moral status; regenerative medicine; blastocyst complementation; research ethics

Citation: Lindqvist G, Greco L and Kovacs S (2023) The Moral Status of Human-Animal Chimeras in Regenerative Medicine. *Bioethics*. 1(2):01-05.

Corresponding Author: Giulia Lindqvist

E-mail Address: g.lindqvist@northmoor.ac.uk

Article History: Received 30 May 2023 | Accepted 04 September 2023 | Published 08 December 2023

Copyright: © 2023 Giulia Lindqvist, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (<https://creativecommons.org/licenses/by/4.0/>).

INTRODUCTION

A chimera, in the biological sense relevant here, is an organism composed of cells from two or more genetically distinct individuals -- and increasingly, from

two distinct species. What was once a laboratory curiosity confined to early developmental biology has become a serious candidate technology for solving the organ shortage: human pluripotent stem cells injected into pig or sheep blastocysts, with the animal's own

organ-forming genes edited out, in the hope that the resulting animal will grow a humanized pancreas, kidney, or heart suitable for transplantation [1]. The same underlying technique, interspecies blastocyst complementation, is being refined and reviewed at a pace that has outstripped the ethical literature's ability to settle basic questions about what, exactly, is being created [2].

The trouble is not merely regulatory. It is conceptual. Human-animal chimera research raises a question that most bioethics does not have to answer directly: how much human biological material, integrated in what way, changes an animal's moral status -- or, in less common but more unsettling scenarios, brings an animal's biology close enough to human that our usual justifications for using animals in research start to look shaky [3]. Public and scientific attention has moved through several waves of concern -- humanized brains, humanized germlines, humanized organs -- and each has forced a slightly different version of the same underlying problem. This paper surveys that literature and the leading frameworks for thinking about moral status in chimeric organisms, focusing on regenerative medicine applications where the ethical stakes and the therapeutic promise are both highest.

FROM MORATORIUM TO GUARDED OPTIMISM: A BRIEF HISTORY OF THE DEBATE

The contemporary chimera debate has a fairly precise origin point. In 2015, the US National Institutes of Health imposed a funding moratorium on research introducing human pluripotent cells into non-human vertebrate embryos, citing unresolved concerns about the possibility of humanizing an animal's brain or germline to a morally significant degree [4]. The following year the agency proposed lifting that moratorium under a revised oversight structure requiring case-by-case review by a dedicated steering committee, a move reported at the time as a cautious opening rather than a wholesale endorsement [5]. Commentators covering the policy shift noted that NIH's own staff scientists were divided on how much oversight was enough, given how little was actually known about what happens when human cells integrate into a developing animal brain [6].

The scientific response to the proposed policy change was itself split. One widely discussed critique argued that the case for chimera research rested on empirical claims -- about organ shortage, about the limits of animal models -- that were often asserted rather than demonstrated, and that regulatory bodies were being asked to weigh speculative benefit against reasonably concrete risk [7]. Later survey work exploring public attitudes found considerably more openness to chimera research than commentators on either side of the scientific debate had assumed, particularly when the stated purpose was organ generation for transplantation rather than basic developmental

biology [8]. That gap between expert anxiety and public pragmatism has persisted and arguably widened as concrete progress on humanized-organ pigs has accumulated [9].

FRAMEWORKS FOR MORAL STATUS: CAPACITY, KIND, AND DEGREE

Most ethical frameworks for thinking about moral status fall into one of two families. Capacity-based accounts hold that moral status tracks morally relevant capacities -- sentience, the ability to suffer, self-awareness, some threshold of cognitive complexity -- regardless of species membership. On this view, a chimeric animal's moral status is a straightforward, if empirically difficult, function of what it can actually feel and do, not of how much human DNA it carries. Kind-based accounts, by contrast, hold that species membership itself carries moral weight independent of any individual's specific capacities, so that an organism sufficiently "humanized" might acquire elevated moral status even without demonstrating any new cognitive capacity, simply by virtue of what it now partly is [10].

A body of philosophical work has tried to split the difference by treating moral status as a matter of degree rather than a binary, arguing that the ethically apt question is not "is this chimera human or not" but "how much, and in what dimension, has this organism's morally relevant profile shifted" [11]. This degree-based framing does useful work for regenerative-medicine chimeras specifically, since a pig carrying humanized pancreatic tissue and a pig carrying a humanized brain plainly warrant different levels of concern even though both are, technically, human-animal chimeras. Baylis and Robert's influential early treatment of the topic pushed in a similar direction, insisting that "part-human chimera" was doing far more rhetorical work in public discourse than the underlying biology could support, and that careful ethical analysis needed to specify which tissue, which proportion, and which developmental stage was actually at issue before drawing conclusions about moral status [12]. Devolder's more recent synthesis largely accepts this framing while emphasizing that uncertainty about an organism's actual capacities -- not merely disagreement about which theory of moral status is correct -- is itself a reason for caution that doesn't depend on resolving the theoretical dispute first [3].

Table 1 summarizes how three influential frameworks would each assess the three chimera types most discussed in the regenerative-medicine literature, and Figure 1 renders the same comparison schematically, showing how concern tracks tissue type rather than the mere fact of chimerism.

HUMANIZED ORGANS: THE REGENERATIVE MEDICINE CASE


Interspecies blastocyst complementation for organ

generation is the application driving most of the recent renewed interest in chimera research, and for good reason: transplant waiting lists have not meaningfully shortened despite decades of policy effort, and xenotransplantation using unmodified animal organs carries well-documented immunological and infectious-disease risks. Generating a humanized organ inside a genetically modified pig -- one whose own organ-forming genes have been deleted so that human donor cells fill the resulting developmental niche -- is a technically elegant solution to both problems at once, at least in principle [13].

Table 1. Three chimera types compared across three moral-status frameworks discussed in the literature.

Chimera type	Capacity-based view	Kind-based view	Degree-based view
Humanized-organ pig (e.g. humanized pancreas)	Low concern -- no evidence of elevated sentience or cognition	Low concern -- species membership essentially unaltered	Low-to-moderate -- concern scales with confinement risk to non-target tissue
Neural chimera / brain organoid transplant	Moderate-to-high concern -- capacity shift cannot be ruled out with current tools	Moderate concern -- depends on how much weight is placed on neural tissue specifically	High -- explicitly the dimension this framework was built to track
Early monkey-human embryo(basic developmental research)	Low concern at current (pre-implantation) stages, contested if gestation were extended	High concern for some theorists regardless of stage, given cross-species developmental competence	Moderate -- degree judged low at current stages, acknowledged as escalating with developmental progression

Figure 1. Schematic comparison of relative ethical concern across three chimera types as discussed in the literature (illustrative synthesis of qualitative positions, not a measured or quantitative scale).



The ethical profile of a "humanized organ" pig differs sharply from that of a humanized-brain or humanized-germline chimera, precisely because the human cell contribution is intentionally restricted to a

single organ system through genetic targeting, and this restriction is doing real ethical work rather than merely reassuring the public [2]. Even so, ambiguity remains about whether human cells introduced early in blastocyst development can be reliably confined to the intended organ, since pluripotent cells are, by definition, capable of contributing to any tissue type before differentiation signals take hold; unwanted integration into neural or germline tissue during complementation remains a live technical and ethical concern that recent gene-editing refinements have reduced but not eliminated [9]. A comprehensive recent review of blastocyst complementation approaches argues that the field has made genuine progress on targeting precision, but cautions that "genuine progress" and "solved problem" are not the same claim, and that ongoing monitoring of chimeric contribution across tissues should remain a condition of continued research rather than a one-time approval hurdle [14].

One persistent philosophical worry specific to this application is what has been called moral uncertainty rather than moral objection: even researchers and ethicists who do not believe humanized-organ pigs have elevated moral status are often unwilling to say they are certain of this, and that uncertainty itself, compounded across a large-scale farming operation raising and slaughtering thousands of such animals for organ harvest, generates an ethical burden distinct from ordinary animal-welfare concerns about livestock [15]. Bourret and colleagues' analysis of chimeric organ farming reaches a related conclusion from a different angle, arguing that scaling this technology to clinically meaningful organ supply will require confronting welfare and governance questions about animal husbandry that the current bioethics literature, focused heavily on the moment of embryo creation, has mostly left unaddressed [16].

NEURAL CHIMERAS AND THE LIMITS OF CONFINEMENT

If humanized organs represent the least ethically fraught end of the chimera spectrum, neural chimeras sit at the opposite end. The core scenario driving concern is straightforward to state and difficult to rule out with confidence: human neural stem or progenitor cells introduced into a developing animal brain might, in principle, contribute enough to cortical circuitry to produce meaningfully human-like cognitive capacities in a non-human animal, capacities that would be very difficult to detect using existing behavioral and neurophysiological measures [17]. Experiments transplanting human cells into rodent brains have already demonstrated functional integration -- human neurons that fire, connect, and influence host circuit activity -- without producing anything resembling humanlike cognition, which is reassuring evidence about mice specifically but does not settle what happens as the technique moves to larger-brained

hosts or larger human cell contributions [18].

A parallel debate concerns human brain organoids -- three-dimensional neural tissue cultures grown from human stem cells without any animal host at all -- and whether transplanting them into animal brains, or growing them to greater maturity in culture, raises comparable moral-status questions even in the absence of a whole-organism chimera. One influential framework proposes assessing organoid and neural-chimera research against six principles spanning the organoid's neural complexity, its capacity for any form of consciousness or sentience, and the transparency of consent processes for the human tissue donors involved, applying the same framework to xenotransplantation scenarios specifically [19]. A related line of argument holds that if an organoid or chimera develops capacities that would ground moral concern in a born human or animal, that concern does not evaporate simply because the tissue in question was never destined to become, or never was, an integrated whole organism -- the moral question tracks capacity, not developmental completeness [20].

More recent work has tried to move past abstract principle-listing toward the practical question of how existing animal-research ethics infrastructure -- institutional animal care committees built around species-typical welfare assessments -- should actually evaluate a neural chimera or organoid transplant that may or may not have crossed into morally significant territory, and has generally concluded that current oversight bodies lack both the expertise and the assessment tools to make that determination reliably [21]. Comparative policy analysis across European jurisdictions has found meaningfully different regulatory postures toward neural chimera research specifically, driven less by differing ethical conclusions than by differing institutional traditions for how precautionary novel biotechnology should be treated by default [22].

BEYOND THE LABORATORY: GENETIC CHIMERISM AT THE SPECIES BOUNDARY

The most philosophically vivid chimera scenarios -- monkey-human embryos combining pluripotent cells from both species in early development -- remain closer to basic developmental biology than to any near-term clinical application, but they sharpen the moral-status debate in ways that organ- and even brain-chimera research do not, because they force explicit engagement with what, if anything, distinguishes a chimera from a hybrid, and what continuities exist between chimera research and other contested areas such as anencephalic organ donation or the moral status of synthetic embryo models [23]. These experiments are typically terminated at very early developmental stages specifically to avoid the harder moral-status questions that would arise from allowing gestation to continue, but critics have argued that the mere demonstration of interspecies

developmental competence is itself ethically significant, independent of whether any particular experiment is carried to term, because it establishes technical feasibility that outpaces society's readiness to decide how such organisms, if gestated, ought to be treated [10].

CONCLUSION

Human-animal chimera research in regenerative medicine is not one ethical problem but several, loosely bundled together by a shared biological technique. Humanized-organ pigs, built through carefully targeted blastocyst complementation, present a comparatively tractable case: the ethical burden is largely about verifying that human cell contribution stays confined to the intended tissue, and about the animal-welfare implications of farming chimeric livestock at clinical scale, rather than about any serious worry that the animals themselves have acquired elevated moral status. Neural chimeras and brain organoid transplants sit much further along the spectrum of concern, precisely because the tissue in question is the one most plausibly linked to capacities -- sentience, self-awareness, something recognizably humanlike -- that most theories of moral status treat as intrinsically significant, and because current detection methods cannot rule out morally relevant integration with full confidence. What both ends of the spectrum share is a persistent gap between the pace of technical progress and the maturity of the oversight frameworks meant to govern it: institutional review structures built for ordinary animal research were not designed to assess whether an animal's moral status has shifted, and the philosophical literature, though increasingly sophisticated about frameworks for degree and kind, has not yet converged on operational criteria those committees could actually apply. Progress on the science, in other words, has not been matched by progress on the governance question of who decides, and by what standard, when a chimera has become something more than an animal.

DECLARATIONS

Acknowledgements

The authors are grateful to colleagues in their respective bioethics centers for helpful discussion of an earlier draft of this review.

Funding

This review received no external funding.

Conflict of Interest

The authors declare no conflicts of interest relevant to this work.

Author Contributions

Giulia Lindqvist conceived the review, coordinated the literature synthesis, and drafted the introduction and conclusion. Lars Greco drafted the sections on

humanized organs and neural chimeras and prepared the accompanying figure. Sofia Kovacs drafted the sections on the historical policy debate and moral-status frameworks and coordinated reference verification. All authors read, revised, and approved the final manuscript.

Ethics Statement

As a literature review synthesizing previously published, publicly available research and policy analysis, this article did not involve new data collection from human participants or animal subjects and did not require institutional ethics committee approval.

Data Availability

No new data were generated or analyzed for this review. All sources discussed are cited in the reference list and are publicly available through their respective publishers.

REFERENCES

1. Generation of human organs in pigs via interspecies blastocyst complementation (2017) *Cell*.
2. The road to generating transplantable organs: from blastocyst complementation to interspecies chimeras (2021) *Development*.
3. Devolder K (2019) The Ethics of Creating and Using Human-Animal Chimeras. *ILAR Journal*.
4. NIH moves to lift moratorium on animal-human chimera research (2016) *Science*.
5. NIH to lift moratorium on human-animal chimera research (2016) *Progress Educational Trust (BioNews)*.
6. NIH considering restarting funding for human-animal chimera research (2016) *STAT News*.
7. What's Wrong with Human/Nonhuman Chimera Research? (2016) *PLOS Biology*.
8. The American Public Is Ready to Accept Human-Animal Chimera Research (2020) *Stem Cell Reports*.
9. Blastocyst complementation and interspecies chimeras in gene edited pigs (2022) *Frontiers/Genes*, PMID:36568986.
10. Chimeras, Moral Status, and Public Policy: Implications of the Abortion Debate for Public Policy on Human/Nonhuman Chimera Research. *Journal of Law, Medicine & Ethics*.
11. DeGrazia D (2007) Human-animal chimeras: human dignity, moral status, and species prejudice. *Metaphilosophy*.
12. Baylis F, Robert JS (2007) Part-Human Chimeras: Worrying the Facts, Probing the Ethics. *American Journal of Bioethics*.
13. Interspecies Chimeras and the Generation of Humanized Organs (2018) *Circulation Research*, DOI:[10.1161/CIRCRESAHA.118.314189](https://doi.org/10.1161/CIRCRESAHA.118.314189).
14. Interspecies Blastocyst Complementation and the Genesis of Chimeric Solid Human Organs (2025) *Genes*.
15. Moral uncertainty and the farming of human-pig chimeras (2019) *Journal of Medical Ethics*, PMID:31256005.
16. Human-animal chimeras: ethical issues about farming chimeric animals bearing human organs (2016) *Stem Cell Research & Therapy*, DOI:[10.1186/s13287-016-0345-9](https://doi.org/10.1186/s13287-016-0345-9).
17. Ethical considerations for human-animal neurological chimera research: mouse models and beyond (2019) *EMBO Journal*, DOI:[10.15252/emboj.2019103331](https://doi.org/10.15252/emboj.2019103331).
18. Transplantation of Human Brain Organoids: Revisiting the Science and Ethics of Brain Chimeras (2019) *American Journal of Bioethics*, PMID:31585092.
19. A Tale of Two Chimeras: Applying the Six Principles to Human Brain Organoid Xenotransplantation (2023) *Cambridge Quarterly of Healthcare Ethics*.
20. Human Brain Organoids: Why There Can Be Moral Concerns If They Grow Up in the Lab and Are Transplanted or Destroyed (2022) *Cambridge Quarterly of Healthcare Ethics*.
21. Human Brain Organoid Transplantation: Testing the Foundations of Animal Research Ethics (2024) *Neuroethics*, DOI:[10.1007/s12152-024-09556-3](https://doi.org/10.1007/s12152-024-09556-3).
22. Human-Animal Chimera: A Neuro Driven Discussion? Comparison of Three Leading European Research Countries (2020) *NanoEthics*.
23. Exploring the Ethics of Creating Chimeric 'Monkey-Human' Embryos: Could Xenotransplantation, the Treatment of Anencephalic Infants, or Synthetic Human Embryos Provide Insights? (2025) *Monash Bioethics Review*, DOI:[10.1080/20502877.2025.2538394](https://doi.org/10.1080/20502877.2025.2538394).